Open AccessParonychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report
Author(s) -
Ahu Yorulmaz,
Başak Yalçın
Publication year - 2019
Publication title -
skin appendage disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.773
H-Index - 13
eISSN - 2296-9195
pISSN - 2296-9160
DOI - 10.1159/000502986
Subject(s) - ibrutinib , medicine , paronychia , dermatology , chronic lymphocytic leukemia , mantle cell lymphoma , adverse effect , bruton's tyrosine kinase , lymphoma , leukemia , tyrosine kinase , receptor
Ibrutinib is an oral covalent inhibitor of the Bruton's tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström's macroglobulinaemia. It is generally a drug of choice for high-risk patients with indolent lymphomas. The safety profile of ibrutinib appears to be tolerable, with well-known side effects such as infections and haematologic complications. Additionally, dermatological adverse reactions with ibrutinib therapy have been reported to encompass maculopapular rash and hair/nail abnormalities. Here, we present a case of ibrutinib-induced paronychia and periungual granulation in a 40-year-old woman. To the best of our knowledge, this is the third description of ibrutinib-induced paronychia and periungual granulation.